Characterization of the postsynaptic protein neurogranin in paired cerebrospinal fluid and plasma samples from Alzheimer’s disease patients and healthy controls
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1758-9193
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Characterization of the postsynaptic protein neurogranin in paired cerebrospinal fluid and plasma samples from Alzheimer’s disease patients and healthy controls ; volume:7 ; number:1 ; day:1 ; month:7 ; year:2015 ; pages:1-9 ; date:12.2015
Alzheimer's research & therapy ; 7, Heft 1 (1.7.2015), 1-9, 12.2015
- Urheber
-
Kvartsberg, Hlin
Portelius, Erik
Andreasson, Ulf
Brinkmalm, Gunnar
Hellwig, Konstantin
Lelental, Natalia
Kornhuber, Johannes
Hansson, Oskar
Minthon, Lennart
Spitzer, Philipp
Maler, Juan M.
Zetterberg, Henrik
Blennow, Kaj
Lewczuk, Piotr
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1186/s13195-015-0124-3
- URN
-
urn:nbn:de:101:1-2019102811384796938231
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:33 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Kvartsberg, Hlin
- Portelius, Erik
- Andreasson, Ulf
- Brinkmalm, Gunnar
- Hellwig, Konstantin
- Lelental, Natalia
- Kornhuber, Johannes
- Hansson, Oskar
- Minthon, Lennart
- Spitzer, Philipp
- Maler, Juan M.
- Zetterberg, Henrik
- Blennow, Kaj
- Lewczuk, Piotr
- SpringerLink (Online service)
Ähnliche Objekte (12)
Characterization of the postsynaptic protein neurogranin in paired cerebrospinal fluid and plasma samples from Alzheimer’s disease patients and healthy controls
Der N-Methyl-D-Aspartat (NMDA)-Rezeptor im menschlichen Gehirn : experimentelle Studien unter besonderer Berücksichtigung der Schizophrenien
Antibodies against phosphorylcholine are not altered in plasma of patients with Alzheimer’s disease
Fluid biomarkers in Alzheimer’s disease – current concepts
Cerebro-spinal fluid biomarker levels: phosphorylated tau (T) and total tau (N) as markers for rate of progression in Alzheimer’s disease
Changes in cerebrospinal fluid and blood plasma levels of IGF-II and its binding proteins in Alzheimer’s disease: an observational study
Blood‐based biomarkers for Alzheimer's disease
[18F]Flortaucipir distinguishes Alzheimer’s disease from progressive supranuclear palsy pathology in a mixed-pathology case
Diversitätsintelligenz
Cognitively normal women with Alzheimer’s disease proteinopathy show relative preservation of memory but not of hippocampal volume
Cerebrospinal fluid soluble TREM2 in aging and Alzheimer’s disease
Advantages and disadvantages of the use of the CSF Amyloid β (Aβ) 42/40 ratio in the diagnosis of Alzheimer’s Disease
Characterization of the postsynaptic protein neurogranin in paired cerebrospinal fluid and plasma samples from Alzheimer’s disease patients and healthy controls
Der N-Methyl-D-Aspartat (NMDA)-Rezeptor im menschlichen Gehirn : experimentelle Studien unter besonderer Berücksichtigung der Schizophrenien
Antibodies against phosphorylcholine are not altered in plasma of patients with Alzheimer’s disease
Fluid biomarkers in Alzheimer’s disease – current concepts
Cerebro-spinal fluid biomarker levels: phosphorylated tau (T) and total tau (N) as markers for rate of progression in Alzheimer’s disease
Changes in cerebrospinal fluid and blood plasma levels of IGF-II and its binding proteins in Alzheimer’s disease: an observational study
Blood‐based biomarkers for Alzheimer's disease
[18F]Flortaucipir distinguishes Alzheimer’s disease from progressive supranuclear palsy pathology in a mixed-pathology case
Diversitätsintelligenz
Cognitively normal women with Alzheimer’s disease proteinopathy show relative preservation of memory but not of hippocampal volume
Cerebrospinal fluid soluble TREM2 in aging and Alzheimer’s disease
Advantages and disadvantages of the use of the CSF Amyloid β (Aβ) 42/40 ratio in the diagnosis of Alzheimer’s Disease
Characterization of the postsynaptic protein neurogranin in paired cerebrospinal fluid and plasma samples from Alzheimer’s disease patients and healthy controls
Der N-Methyl-D-Aspartat (NMDA)-Rezeptor im menschlichen Gehirn : experimentelle Studien unter besonderer Berücksichtigung der Schizophrenien
Antibodies against phosphorylcholine are not altered in plasma of patients with Alzheimer’s disease
Fluid biomarkers in Alzheimer’s disease – current concepts
Cerebro-spinal fluid biomarker levels: phosphorylated tau (T) and total tau (N) as markers for rate of progression in Alzheimer’s disease
Changes in cerebrospinal fluid and blood plasma levels of IGF-II and its binding proteins in Alzheimer’s disease: an observational study
Blood‐based biomarkers for Alzheimer's disease
[18F]Flortaucipir distinguishes Alzheimer’s disease from progressive supranuclear palsy pathology in a mixed-pathology case
Diversitätsintelligenz
Cognitively normal women with Alzheimer’s disease proteinopathy show relative preservation of memory but not of hippocampal volume
Cerebrospinal fluid soluble TREM2 in aging and Alzheimer’s disease